LINEAGE CELL THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Alfred D. Kingsley

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alfred D. Kingsley”): 71,157,090 for, 4,219,310 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 11,326,042 for, 768,400 withheld.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Angus C. Russell”): 55,755,116 for, 19,621,284 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 125,549 for, 11,968,893 withheld.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anula Jayasuriya”): 73,404,130 for, 1,972,270 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 11,327,342 for, 767,100 withheld.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Brian M. Culley”): 74,426,506 for, 949,894 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 12,094,442 for.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Deborah Andrews”): 74,096,073 for, 1,280,327 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 12,093,142 for, 1,300 withheld.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dipti Amin”): 74,273,372 for, 1,103,028 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 12,093,142 for, 1,300 withheld.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Don M. Bailey

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Don Bailey”): 73,391,291 for, 1,985,109 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 11,327,342 for, 767,100 withheld.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael H. Mulroy”): 63,115,746 for, 12,260,654 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 5,671,015 for, 6,423,427 withheld.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Neal C. Bradsher”): 73,396,208 for, 1,980,192 withheld, per its Form 8-K filed September 7, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the nine nominees named below to the Company's board of directors to hold office until the Company's 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 11,315,386 for, 779,056 withheld.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Angus C. Russell”): 90,523,578 for, 1,740,111 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the nine nominees named below to the Board to hold office until the Company's 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 9,426,299 for, 1,300 withheld.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anula Jayasuriya”): 89,952,809 for, 2,310,880 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the nine nominees named below to the Board to hold office until the Company's 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 8,807,842 for, 619,757 withheld.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Brian M. Culley”): 90,475,144 for, 1,788,545 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the nine nominees named below to the Board to hold office until the Company's 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 9,427,599 for.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Deborah Andrews”): 90,481,681 for, 1,782,008 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the nine nominees named below to the Board to hold office until the Company's 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 9,427,599 for.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dipti Amin”): 90,605,789 for, 1,657,900 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the nine nominees named below to the Board to hold office until the Company's 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 9,427,599 for.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Don M. Bailey

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Don M. Bailey”): 89,860,655 for, 2,403,034 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the nine nominees named below to the Board to hold office until the Company's 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 8,807,842 for, 619,757 withheld.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael H. Mulroy”): 90,809,616 for, 1,454,073 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the nine nominees named below to the Board to hold office until the Company's 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 9,426,299 for, 1,300 withheld.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Neal C. Bradsher”): 90,181,941 for, 2,080,755 withheld, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the nine nominees named below to the Board to hold office until the Company's 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 8,795,886 for, 631,713 withheld.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR ARTICLES OF INCORPORATION TO INCREASE THE NUMBER OF OUR AUTHORIZED COMMON SHARES FROM 250,000,000 TO 450,000,000.

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“6. An amendment to the Company's restated articles of incorporation to increase the number of authorized common shares from 250,000,000 to 450,000,000”): 108,314,123 for, 10,203,002 against — passed, per its Form 8-K filed September 7, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved an amendment to the Company's restated articles of incorporation to increase the number of authorized common shares from 250,000,000 to 450,000,000 by the votes set forth below.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 12,094,442 for.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE MEETING, IF NECESSARY OR ADVISABLE, TO SOLICIT ADDITIONAL PROXIES IN FAVOR OF PROPOSAL 6 IF THERE ARE NOT SUFFICIENT VOTES TO APPROVE PROPOSAL 6.

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“7. The adjournment of the Annual Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 in the event there are not sufficient votes to approve Proposal 6”): 108,130,223 for, 10,087,729 against — passed, per its Form 8-K filed September 7, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 7: The Company's shareholders approved the adjournment of the Annual Meeting, if necessary or advisable, to solicit additional proxies in favor of ”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 11,868,394 for, 226,048 against.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE LINEAGE CELL THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF COMMON SHARES AVAILABLE THEREUNDER BY 19,500,000.

The 30 asset managers below reported 10,914,188 for, 1,180,254 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“3. On an advisory and non-binding basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement”): 70,271,698 for, 4,542,895 against — passed, per its Form 8-K filed September 7, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved, on an advisory and non-binding basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the votes set forth below.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 29 managers: 11,315,386 for, 777,756 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 89 managers: 11,235,319 for, 119,061 against, 65,697 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 29 managers: 12,084,442 1 year, 8,700 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 89 managers: 71,213 for, 177 against, 10,373,939 1 year, 31,849 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“3. The compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes”): 87,812,598 for, 3,704,495 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 22 managers: 8,499,064 for, 619,757 against.

Institutional-manager reports, all 74 managers: 18,889,377 for, 83,959 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2023.

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“2. The appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023”): 118,493,370 for, 481,961 against — passed, per its Form 8-K filed September 7, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's shareholders ratified the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, by the votes set forth below.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 12,094,442 for.

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

Description as filed by funds: To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2024.

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“2. The appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following votes”): 128,607,948 for, 2,400,322 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Shareholders ratified the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 9,427,599 for.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.